Iovance Biotherapeutics logo
Iovance Biotherapeutics IOVA
$ 6.9 -5.61%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Iovance Biotherapeutics Net Income | IOVA

Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.

Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]

It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.

The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.

Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.

It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.

However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.

Annual Net Income Iovance Biotherapeutics

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
-391 M -372 M -444 M -396 M -342 M -260 M -198 M -124 M -92.1 M -52.9 M -27.7 M -12 M -25.4 M -3.31 M -25.7 M -1.61 M -15.8 K -58.7 K -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-15.8 K -444 M -154 M

Quarterly Net Income Iovance Biotherapeutics

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-22.3 M -47.3 M -79 M -71.9 M -91.3 M -112 M -116 M -78.6 M -83.5 M -97.1 M -113 M -116 M -114 M -107 M -107 M - -99.6 M -99.3 M -91.6 M - -86.1 M -81.4 M -75.4 M -68.4 M -58.6 M -63 M -69.6 M -63.6 M -49.5 M -47.6 M -37 M -32.6 M -33.8 M -30.7 M -26.5 M -25.9 M -22.1 M -23.4 M -20.7 M -15.7 M -68.2 M -11.6 M -6.88 M -8.36 M -7.64 M -6.37 M -5.3 M -4.65 M -3.01 M -2.11 M -2.26 M - -9.41 M -3.43 M -1.05 M - -674 K -327 K -5.77 M - -5.82 M -11 M -564 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
-327 K -116 M -47.3 M

References

  1. Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.

Net Income of other stocks in the Biotechnology industry

Issuer Net Income Price % 24h Market Cap Country
Outlook Therapeutics Outlook Therapeutics
OTLK
-62.4 M $ 0.39 -2.79 % $ 13.6 M usaUSA
uniQure N.V. uniQure N.V.
QURE
-199 M $ 19.32 -4.5 % $ 1.11 B niderlandNiderland
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
-575 M $ 16.46 -4.41 % $ 1.62 B usaUSA
Rafael Holdings Rafael Holdings
RFL
-29.6 M $ 0.94 5.89 % $ 48.3 M usaUSA
REGENXBIO REGENXBIO
RGNX
-194 M $ 7.16 -0.35 % $ 369 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
367 M $ 40.05 -2.78 % $ 720 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
14.5 M - -6.63 % $ 13.9 M usaUSA
I-Mab I-Mab
IMAB
-1.47 B - - $ 866 M chinaChina
Tenax Therapeutics Tenax Therapeutics
TENX
-52.6 M $ 1.27 -8.27 % $ 49.8 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
603 M - - $ 40.3 B usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
3.95 B $ 514.68 -1.15 % $ 132 B usaUSA
Genfit SA Genfit SA
GNFT
1.51 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
-17 M - -13.47 % $ 169 M franceFrance
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
-26.9 M $ 13.67 -8.01 % $ 1.49 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
162 M - - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
-40 M - 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
-8.5 M - - $ 4.9 B britainBritain
Rezolute Rezolute
RZLT
-77.6 M $ 3.92 -6.69 % $ 407 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.38 M - -18.52 % $ 27.3 M britainBritain
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
-11.9 M $ 0.63 -7.05 % $ 67.2 M britainBritain
MorphoSys AG MorphoSys AG
MOR
-190 M - 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
-106 M - -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
-102 M - -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
-40.9 M - - $ 12.5 M belgiumBelgium
Seer Seer
SEER
-73.6 M $ 1.34 -3.25 % $ 74.5 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
-608 M - - $ 3.37 B chinaChina
Summit Therapeutics Summit Therapeutics
SMMT
-1.08 B $ 9.94 -6.01 % $ 7.43 B britainBritain
Shattuck Labs Shattuck Labs
STTK
-48.8 M $ 4.49 -1.43 % $ 312 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
-43.3 M $ 19.81 0.08 % $ 2.81 B britainBritain
Soligenix Soligenix
SNGX
-11.1 M $ 0.22 -8.25 % $ 1.14 M usaUSA
Sanofi Sanofi
SNY
7.85 B $ 46.51 0.97 % $ 56.8 B franceFrance
Spruce Biosciences Spruce Biosciences
SPRB
-39 M $ 38.02 -6.11 % $ 29.1 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
8.57 M $ 0.74 -10.95 % $ 41.5 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
-713 M $ 13.34 -5.86 % $ 1.34 B usaUSA
Savara Savara
SVRA
-119 M $ 4.28 -17.95 % $ 952 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
-25.1 M - -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
-151 M - - $ 2.91 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
-191 M $ 8.6 -1.38 % $ 73.1 M usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
-66 M $ 72.94 -6.09 % $ 3.05 B usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
-38.6 M $ 36.28 1.88 % $ 2.05 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
447 M $ 63.39 -2.3 % $ 9.15 B usaUSA
Aphria Inc. Aphria Inc.
APHA
-84.6 M - -0.45 % $ 4.87 B canadaCanada
Viridian Therapeutics Viridian Therapeutics
VRDN
-343 M $ 29.91 -4.87 % $ 3.05 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
-42.8 M $ 13.35 -2.73 % $ 1.8 B usaUSA
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
-4.32 M - -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
-74.8 M - -6.00 % $ 238 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
-27 M $ 16.0 -2.2 % $ 64.2 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
-57.4 M - - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
16.8 M - 0.38 % $ 12.9 M israelIsrael